Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of JNJ-66525433 in Healthy Participants and Participants with Ulcerative Colitis
NCT04457960Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing JNJ-66525433 with Placebo (2 arms). Primary endpoints: Treatment-emergent Adverse Events up to 224 Days, Vital Sign Abnormalities up to 224 Days and 5 more. Started Jul 2020; status: terminated.
02
Drugs
JNJ-66525433
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04457960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457960.